Sale!

Immunohistochemistry Prostate Benign vs Malignant Panel Test Cost

Original price was: 910 د.إ.Current price is: 820 د.إ.

-10%

The Immunohistochemistry Prostate Benign vs Malignant Panel Test is a specialized diagnostic procedure used to differentiate between benign (non-cancerous) and malignant (cancerous) prostate conditions. This test employs immunohistochemistry (IHC), a technique that uses antibodies to detect specific antigens in a sample of prostate tissue, allowing for the visualization of proteins directly involved in the pathology of prostate diseases. By examining the expression and localization of these proteins, pathologists can provide crucial information regarding the nature of the prostate condition, aiding in the accurate diagnosis and guiding treatment decisions.

Performed at DNA Labs UAE, a leading facility known for its advanced diagnostic technologies and expert staff, this test offers a comprehensive analysis. The cost of the Immunohistochemistry Prostate Benign vs Malignant Panel Test is 820 AED. Given the complexity and the detailed insights it provides, this test is a valuable tool for urologists and oncologists in the management of patients with prostate conditions, helping to distinguish between conditions that may require different therapeutic approaches.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

IMMUNOHISTOCHEMISTRY PROSTATE BENIGN VS MALIGNANT PANEL Test

Test Name: IMMUNOHISTOCHEMISTRY PROSTATE BENIGN VS MALIGNANT PANEL Test

Test Components: AMACR, CK5/6, p63

Price: 820.0 AED

Sample Condition: Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.

Report Delivery: Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex: 7 days

Method: Immunohistochemistry

Test type: Cancer

Doctor: Oncologist, Pathologist

Test Department: HISTOLOGY

Pre Test Information: Provide a copy of the Histopathology report, Site of biopsy and Clinical history.

Test Details

Immunohistochemistry (IHC) is a technique used in pathology to detect specific proteins in tissue samples. In the case of prostate cancer, IHC can be used to distinguish between benign and malignant cells by identifying the presence or absence of certain markers.

A panel of IHC markers commonly used to differentiate between benign and malignant prostate cells includes:

  1. Prostate-specific antigen (PSA): PSA is a protein produced by the prostate gland. It is typically elevated in prostate cancer but may also be present in benign conditions such as benign prostatic hyperplasia (BPH). However, PSA staining alone is not sufficient to differentiate between benign and malignant cells.
  2. High molecular weight cytokeratin (HMWCK): HMWCK is a marker of basal cells in the prostate gland. In benign prostate tissue, basal cells are typically present, while they are absent in malignant cells. Therefore, positive staining for HMWCK indicates benign cells, while negative staining suggests malignancy.
  3. P63: P63 is another marker of basal cells in the prostate gland. Similar to HMWCK, positive staining for P63 indicates benign cells, while negative staining suggests malignancy.
  4. Alpha-methylacyl-CoA racemase (AMACR): AMACR is an enzyme involved in fatty acid metabolism. It is overexpressed in prostate cancer cells but is usually absent in benign cells. Positive staining for AMACR indicates malignancy.
  5. Ki-67: Ki-67 is a marker of cell proliferation. It is typically higher in malignant cells compared to benign cells. High Ki-67 staining suggests increased cell proliferation and is indicative of malignancy.

By analyzing the staining patterns of these markers, pathologists can determine whether the prostate tissue is benign or malignant. However, it is important to note that the interpretation of IHC results should be done in conjunction with other clinical and pathological findings to arrive at an accurate diagnosis.

Test Name IMMUNOHISTOCHEMISTRY PROSTATE BENIGN VS MALIGNANT PANEL Test
Components *AMACR*CK5/6*p63
Price 820.0 AED
Sample Condition Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex : 7 days
Method Imunohistochemistry
Test type Cancer
Doctor Oncologist, Pathologist
Test Department: HISTOLOGY
Pre Test Information Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Details

Immunohistochemistry (IHC) is a technique used in pathology to detect specific proteins in tissue samples. In the case of prostate cancer, IHC can be used to distinguish between benign and malignant cells by identifying the presence or absence of certain markers.

A panel of IHC markers commonly used to differentiate between benign and malignant prostate cells includes:

1. Prostate-specific antigen (PSA): PSA is a protein produced by the prostate gland. It is typically elevated in prostate cancer but may also be present in benign conditions such as benign prostatic hyperplasia (BPH). However, PSA staining alone is not sufficient to differentiate between benign and malignant cells.

2. High molecular weight cytokeratin (HMWCK): HMWCK is a marker of basal cells in the prostate gland. In benign prostate tissue, basal cells are typically present, while they are absent in malignant cells. Therefore, positive staining for HMWCK indicates benign cells, while negative staining suggests malignancy.

3. P63: P63 is another marker of basal cells in the prostate gland. Similar to HMWCK, positive staining for P63 indicates benign cells, while negative staining suggests malignancy.

4. Alpha-methylacyl-CoA racemase (AMACR): AMACR is an enzyme involved in fatty acid metabolism. It is overexpressed in prostate cancer cells but is usually absent in benign cells. Positive staining for AMACR indicates malignancy.

5. Ki-67: Ki-67 is a marker of cell proliferation. It is typically higher in malignant cells compared to benign cells. High Ki-67 staining suggests increased cell proliferation and is indicative of malignancy.

By analyzing the staining patterns of these markers, pathologists can determine whether the prostate tissue is benign or malignant. However, it is important to note that the interpretation of IHC results should be done in conjunction with other clinical and pathological findings to arrive at an accurate diagnosis.